nur weil 2 Leute das Unternehmen verlassen??

Also bei diesem Absturz sollte doch sicherlich die nächsten Tage was zu holen sein.
Grund für die bisher 30% Minus scheint diese Nachricht zu sein

"BATON ROUGE, La.--(BUSINESS WIRE)--Amedisys, Inc. (NASDAQ: AMED) (the “Company”), one of America's leading home health and hospice nursing companies, today announced that two executives are leaving the Company to pursue other interests. The Company has accepted the resignation of Mr. Larry R. Graham, as President and Chief Operating Officer of the Company. The resignation is effective September 3, 2009. Mr. Graham's duties will be temporarily assumed by William F. Borne, the Company's Chairman and Chief Executive Officer.

The Company also announced the departure of Chief Information Officer Alice Ann Schwartz, effective September 3, 2009.

"We are grateful to Larry and Alice Ann for their contributions throughout the years,” said Mr. Borne. “We anticipate a seamless transition, as we have a first-class team of seasoned professionals that are ready and able to guide our future growth strategies. We believe our future in healthcare has never been brighter."

http://www.businesswire.com/portal/site/google/...524&newsLang=en


hier die Q2 Zahlen
http://www.amedisys.com/pdf/072809_AMED_Q2_Earnings_2.pdf

was meint ihr dazu??  

und dem downgrade von letzter woche (s.u.). da kommt es nicht gut wenn die spitze rausgeworfen wird.

Amedisys shares fall as UBS downgrades on value
By: The Associated Press | 26 Aug 2009 | 12:38 PM ET
Text Size

NEW YORK - Shares of home health and hospice provider Amedisys Inc. fell Wednesday after a UBS analyst downgraded the stock, citing its valuation.

The stock slid $1.16, or 2.6 percent, to $44.08 in afternoon trading. Shares have ranged between $25.20 and $59.24 over the last 52 weeks.

UBS analyst Donald H. Hooker lowered his rating to "Neutral" from "Buy," citing a 54 percent increase in stock value since the middle of June. He reaffirmed a $46 price target.

"There may be incremental upside to both our estimates and price target in the coming months/quarters to the extent that Amedisys is able to continue to find accretive acquisitions," he wrote in a note to investors.

His primary concern remains the potential for a $9 trillion federal budget deficit, which he said could put more pressure on the government to find savings in the Medicare system. That raises the risk of incremental Medicare reimbursement cuts, which could effect Amedisys' revenue.

The next major catalyst for the stock is health care legislation, he said, which could occur in autumn.

"It is our view that home nursing is relatively politically more exposed to reimbursement cuts than other areas," he wrote. "We expect to get more clarity on the Medicare reimbursement environment incrementally over the next couple of months."

http://www.cnbc.com/id/32568509/for/cnbc/  

so long  

und selbst der Artikel von Cnbc liest sich jetzt nicht nur negativ.
Und man muss ja auch sagen, dass die 2 Herren angeblich freiwillig gehen und net entlassen werden  

ist eigentlich immer ein solider wert gewesen. den hatte ich 2006 bis mitte 2007 mal im depot.  

was denkst du, wo landen wir am Ende des Tages?Und das denkst du sind die Aussichten für die nächsten Tage, zumal man ja bedenken muss, dass morgen Freitag ist und die Amis da gerne Gewinne mintnehmen...

Hab vorhin leider den Einstieg beim Tiefsstand verpasst...im Augenblick gehts ja wieder leicht runter...vom Tiefsstand bis jetzt hätte man mal locker 10% mitnehmen können  

Hier könnte in den nächsten Monaten eine kräftige Erholung anstehen!

Bin mal mit ein paar Stücken rein.  

angeschaut und werde nächste Woche wohl auch einsteigen.
Die Zahlen sehen meiner Meinung nach gut aus, und die Firma ist weiter auf Wachstumskurs.
Man sollte auch nicht vergessen, dass vor kurzem ein Aktienrückkauf im Wert von 60 Millionen  Dollar bis Ende Sept 2011 genehmigt wurde, dies würde aktuell ca 10% der Aktien bedeuten.

Three-Month Periods Ended June 30, 2010 and 2009

   * Net service revenue increased $44.4 million or 11.8% to $422.3 million compared to $377.9 million in 2009, with $33.6 million of the increase related to growth through base/start-up agencies.
   * Net income attributable to Amedisys, Inc. decreased $2.9 million or 8.2% to $32.2 million compared to $35.1 million in 2009.
   * Diluted earnings per share decreased 11.0% to $1.13 compared to $1.27 per diluted share in 2009. The weighted average number of diluted shares outstanding increased to approximately 28.6 million compared to 27.5 million in 2009.
   * Earnings before interest, taxes, depreciation and amortization (“EBITDA”) decreased 5.9% to $63.4 million compared to $67.4 million in 2009.

Six-Month Periods Ended June 30, 2010 and 2009

   * Net service revenue increased $115.6 million or 16.1% to $835.3 million compared to $719.7 million in 2009, with $92.3 million of the increase related to growth through base/start-up agencies.
   * Net income attributable to Amedisys, Inc. increased $6.7 million or 10.9% to $68.8 million compared to $62.1 million in 2009
   * Diluted earnings per share increased 7.1% to $2.42 compared to $2.26 per diluted share in 2009. The weighted average number of diluted shares outstanding increased to approximately 28.5 million compared to 27.4 million in 2009.
   * EBITDA increased 10.5% to $134.1 million compared to $121.3 million in 2009.

$60 Million Share Repurchase Program

On August 6, 2010, our Board of Directors authorized a stock repurchase program of up to $60.0 million of our common stock. Purchases may be made through open market and privately negotiated transactions, at times and in such amounts as management deems appropriate, including pursuant to one or more Rule 10b5-1 trading plans. The share repurchase program is scheduled to expire on September 30, 2011.

The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the price of our common stock, corporate and regulatory requirements, restrictions under our debt obligations and other market and economic conditions. The stock repurchase program does not obligate Amedisys to acquire any particular amount of stock and may be modified, suspended or discontinued at any time.

“Although our results for the second quarter were below our expectations we are optimistic about our future and the action plans that we have put into place to revitalize our growth,” stated William F. Borne, Chief Executive Officer of Amedisys, Inc.

Updated 2010 Guidance

   * Net service revenue is anticipated to be in the range of $1.625 billion to $1.650 billion, excluding the effects of future acquisitions, if any are made.
   * Diluted earnings per share is expected to be in the range of $4.20 to $4.50 based on an estimated 28.8 million shares outstanding. This guidance does not include the effects of any share repurchases or the effects of future acquisitions, if any are made.

http://www.businesswire.com/news/home/20100809005545/en  

Firmen.

Hier die Kriterien

http://www.marketwatch.com/story/...s-2010-08-19?reflink=MW_news_stmp

hier die Gesamtliste....letztes Jahr Platz 80, dieses Jahr Platz 47

http://money.cnn.com/magazines/fortune/...testgrowing/2010/full_list/  

sieht gut aus....  

https://www.marketscreener.com/AMEDISYS-INC-8342/...napshot-30015348/

Amedisys: 4Q Earnings Snapshot
share with twitter share with LinkedIn share with facebook share via e-mail
0
02/18/2020 | 10:36pm BST
BATON ROUGE, La. (AP) _ Amedisys Inc. (AMED) on Tuesday reported fourth-quarter earnings of $27.7 million.

The Baton Rouge, Louisiana-based company said it had profit of 83 cents per share. Earnings, adjusted for non-recurring costs, were 94 cents per share.

The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 93 cents per share.

The home health care and hospice services provider posted revenue of $500.7 million in the period, falling short of Street forecasts. Seven analysts surveyed by Zacks expected $510.4 million.

For the year, the company reported profit of $126.8 million, or $3.84 per share. Revenue was reported as $1.96 billion.

Amedisys expects full-year earnings in the range of $4.90 to $5.13 per share, with revenue in the range of $2.12 billion to $2.16 billion.

Amedisys shares have risen 21% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $202.02, an increase of 48% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AMED at https://www.zacks.com/ap/AMED